Cover Image

Novel MDM2 Inhibitor XR-2 Exerts Potent Anti-Tumor Efficacy and Overcomes Enzalutamide Resistance in Prostate Cancer

Background: The inactivation of tumor-suppressor p53 plays an important role in second generation anti-androgens (SGAs) drug resistance and neuroendocrine differentiation in castration-resistant prostate cancer (CRPC). The reactivation of p53 by blocking the MDM2-p53 interaction represents an attrac...

Full description

Saved in:

Bibliographic Details
Main Authors:	Meng Wu (Author), Jingyi Cui (Author), Huimin Hou (Author), Ying Li (Author), Shengjie Liu (Author), Li Wan (Author), Lili Zhang (Author), Wei Huang (Author), Gaoyuan Sun (Author), Jingchao Liu (Author), Pengfei Jin (Author), Shunmin He (Author), Ming Liu (Author)
Format:	Book
Published:	Frontiers Media S.A., 2022-04-01T00:00:00Z.
Subjects:	article
Online Access:	Connect to this object online.
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

MDM2 inhibitor APG-115 synergizes with ABT-199 to induce cell apoptosis in chronic lymphocytic leukemia
by: Ying Cui, et al.
Published: (2024)

TRIB3 promotes pulmonary fibrosis through inhibiting SLUG degradation by physically interacting with MDM2
by: Xiaoxi Lv, et al.
Published: (2023)

Homo-PROTAC mediated suicide of MDM2 to treat non-small cell lung cancer
by: Shipeng He, et al.
Published: (2021)

MDM2 antagonists promote CRISPR/Cas9-mediated precise genome editing in sheep primary cells
by: Yan Li, et al.
Published: (2023)

Searching for novel MDM2/MDMX dual inhibitors through a drug repurposing approach
by: Keting Li, et al.
Published: (2024)

Abiraterone, Orteronel, Enzalutamide and Docetaxel: Sequential or Combined Therapy?
by: Ming-kun Chen, et al.
Published: (2022)

MDM2 Is Essential to Maintain the Homeostasis of Epithelial Cells by Targeting p53
by: Su Wang, et al.
Published: (2024)

Overexpression of CCDC69 activates p14ARF/MDM2/p53 pathway and confers cisplatin sensitivity
by: Long Cui, et al.
Published: (2019)

A novel inhibitor of ARfl and ARv7 induces protein degradation to overcome enzalutamide resistance in advanced prostate cancer
by: Yan Li, et al.
Published: (2022)

K-Ras-ERK1/2 accelerates lung cancer cell development via mediating H3K18ac through the MDM2-GCN5-SIRT7 axis
by: Ziming Cheng, et al.
Published: (2019)

ZLM-7 Blocks Breast Cancer Progression by Inhibiting MDM2 via Upregulation of 14-3-3 Sigma
by: Min Wen, et al.
Published: (2022)

Effect of N-methyl deuteration on metabolism and pharmacokinetics of enzalutamide
by: Jiang J, et al.
Published: (2016)

XR Programmers Give Their Perspective on How XR Technology can be Effectively Utilised in High-Performance Sport
by: Peter J. Le Noury, et al.
Published: (2023)

Detection of P53 and Mdm2 in vitiligo
by: Viroj Wiwanitkit
Published: (2013)

Controlled Study of Guanfacine XR in ADHD
by: J Gordon Millichap
Published: (2008)

Discovery of a highly potent and orally available importin-β1 inhibitor that overcomes enzalutamide-resistance in advanced prostate cancer
by: Jia-Luo Huang, et al.
Published: (2023)

Immunohistochemical detection of P53 and Mdm2 in vitiligo
by: Ola A Bakry, et al.
Published: (2012)

Controlling the Mdm2-Mdmx-p53 Circuit
by: David L. Waning, et al.
Published: (2010)

Identification of a small-molecule RPL11 mimetic that inhibits tumor growth by targeting MDM2-p53 pathway
by: Bingwu Wang, et al.
Published: (2022)

Feasibility of Developing Radiotracers for MDM2: Synthesis and Preliminary Evaluation of an <sup>18</sup>F-Labeled Analogue of the MDM2 Inhibitor SP-141
by: Satish K. Chitneni, et al.
Published: (2021)

XR and Shadow Wars - the Uncanny Valley of Death
by: Slawomir Nikiel
Published: (2020)

Randomized, Controlled Study of Adderall XR in ADHD
by: J Gordon Millichap
Published: (2002)

Effect of Food on Absorption of Dilantin and Mylan XR
by: J Gordon Millichap
Published: (2001)

Long-Term Effects of Adderall XR in ADHD
by: J Gordon Millichap
Published: (2005)

An optimized caries model of Streptococcus mutans in rats and its application for evaluating prophylactic vaccines
by: Bowen Liu, et al.
Published: (2024)

Synthesis of Amino Acids Bearing Halodifluoromethyl Moieties and Their Application to p53-Derived Peptides Binding to Mdm2/Mdm4
by: Vaas S, et al.
Published: (2023)

The SWIB/MDM2 motif of UBE4B activates the p53 pathway
by: H. Helena Wu, et al.
Published: (2023)

SATB2 and MDM2 Immunoexpression and Diagnostic Role in Primary Osteosarcomas of the Jaw
by: Adepitan A. Owosho, et al.
Published: (2021)

p53 and MDM2 protein expression in actinic cheilitis
by: Maria da Conceição Andrade de Freitas, et al.
Published: (2008)

Design of ultrahigh-affinity and dual-specificity peptide antagonists of MDM2 and MDMX for P53 activation and tumor suppression
by: Xiang Li, et al.
Published: (2021)

Inhibiting β-Catenin by β-Carboline-Type MDM2 Inhibitor for Pancreatic Cancer Therapy
by: Jiang-Jiang Qin, et al.
Published: (2018)

Role of gabapentin enacarbil XR in restless legs syndrome
by: Yee BJ, et al.
Published: (2012)

Association of TP53 rs1042522 G > C, MDM2 rs2279744 T > G, and miR-34b/c rs4938723 T > C polymorphisms with aneuploidy pregnancy susceptibility
by: Ying Chan, et al.
Published: (2023)

Motorcycle Dolly Mover version 2 (MDM2) / Suhaimi Nayan ... [et al.]
by: Nayan, Suhaimi, et al.
Published: (2023)

Celecoxib Exerts a Therapeutic Effect Against Demyelination by Improving the Immune and Inflammatory Microenvironments
by: Cao P, et al.
Published: (2020)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
by: Rodriguez-Vida A, et al.
Published: (2015)

Endometrial stromal sarcomas with BCOR‐rearrangement harbor MDM2 amplifications
by: Felix KF Kommoss, et al.
Published: (2020)

Adding Enzalutamide to First-Line Treatment for Metastatic Hormone-Sensitive Prostate Cancer: A Cost-Effectiveness Analysis
by: Peng-Fei Zhang, et al.
Published: (2021)

Tetrandrine targeting SIRT5 exerts anti-melanoma properties via inducing ROS, ER stress, and blocked autophagy
by: Yacong Ji, et al.
Published: (2024)

Allosteric inhibition of HSP70 in collaboration with STUB1 augments enzalutamide efficacy in antiandrogen resistant prostate tumor and patient-derived models
by: Pengfei Xu, et al.
Published: (2023)